The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
|Articles|September 12, 2022
The Mainstream Patient: September 12
Author(s)Kaitlyn Bader, Associate Editor
This week's edition of the Mainstream Patient features stories about the best retinol creams, the Blue Beauty movement, lip blushing, and more.
Advertisement
In this week’s edition, Self lists 17 best retinol creams and serums and Vogue talks with Jennifer Lawrence about motherhood and Roe V. Wade. Cosmopolitan discusses the new movement of Blue Beauty and Glamour reflects on tattoo removals. Elle gives more details on lip blushing and Allure explains how to build a skin care routine while having a heart condition.
The 17 Best Retinol Creams and Serums, According to Dermatologists
Jennifer Lawrence Talks Motherhood, Causeway, and the End of Roe v. Wade
Blue Beauty: What You Need to Know About the Growing (and Incredibly Important) Movement
Tattoo Removal: 14 Things I Wish I Had Known Before Getting It
What You Need to Know About Lip Blushing, the ‘Tattoo’ for Fuller Lips
How to Build a Skin-Care Routine If You Have a Heart Condition
Advertisement
Related to this article
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
Topical vs Oral JAK Inhibitors for Vitiligo: How to Choose as Systemic Options Advance
4
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
5